RecruitingNot ApplicableNCT05661383

Olfactory and Brain Stimulations in Treatment-resistant Depression

Combining Hedonic Olfactory and BRAin Stimulations in Treatment-resistant Depression


Sponsor

Hôpital le Vinatier

Enrollment

80 participants

Start Date

Jan 27, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This is a prospective, randomized, double-blind, parallel-group controlled trial. The aim of this research project is to compare the clinical benefits achieved in patients with major depressive disorder (MDD) following two types of intervention: iTBS active alone or iTBS active combined with olfactory stimulations.


Eligibility

Min Age: 18 Years

Inclusion Criteria4

  • had a primary diagnosis of single-episode or recurrent non-psychotic major depressive disorder according to Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) criteria;
  • scored 20 or over on the MADRS (Montgomery-Åsberg Depression Rating Scale) (Montgomery and Åsberg, 1979) and scored higher than 2 on the MADRS item 8 anhedonia factor score;
  • a stable antidepressant medication for 4 weeks prior to inclusion; be able to speak and read French;
  • sign a consent form before intervention.

Exclusion Criteria5

  • a pre-existing condition that affects olfaction including congenital anosmia, upper respiratory tract infection, nasal and/or sinus disease, brain injury or nasal surgery; a neurological disease;
  • other comorbid psychiatric disorders or substance abuse (except tobacco);
  • contraindications to TMS (medical devices implanted or metallic foreign body in the head);
  • pregnant or lactating mothers (controlled by urine pregnancy tests);
  • measure of protection or guardianship of justice.

Interventions

DEVICENon-invasive brain stimulation protocol (intermittent theta burst protocol (iTBS)) combined with pleasant odors delivered during the iTBS procol.

Device: MagPro X100 (MagVenture, Mag2Health, France) iTBS protocol targeting the left dorsolateral prefrontal cortex: 50 consecutive sessions allocated on 10 days (i.e., 5 sessions per working day, 1 hour apart, for 2 weeks). One iTBS session: burst of 3 pulses at 50 Hz repeated at 200 ms intervals for 2 s (i.e., at 5 Hz) at an intensity of 90% of rMT. A 2 s train of iTBS will be repeated every 10 s for a total of 1800 pulses per session. Pleasant odorants will be delivered using passive diffusers placed in the room dedicated to the iTBS protocol, during the all-treatment duration. During the inclusion phase, 10 odors known to be pleasant will be presented to the subject. The 3 best rated by the subject will be chosen for olfactory stimulations. During the iTBS session, a randomly selected odor from the 3 will be presented at the same time as the iTBS treatment.

DEVICENon-invasive brain stimulation protocol (intermittent theta burst protocol (iTBS)) delivered alone.

Device: MagPro X100 (MagVenture, Mag2Health, France) iTBS protocol targeting the left dorsolateral prefrontal cortex: 50 consecutive sessions allocated on 10 days (i.e., 5 sessions per working day, 1 hour apart, for 2 weeks). One iTBS session: burst of 3 pulses at 50 Hz repeated at 200 ms intervals for 2 s (i.e., at 5 Hz) at an intensity of 90% of rMT. A 2 s train of iTBS will be repeated every 10 s for a total of 1800 pulses per session.


Locations(1)

CH Le Vinatier

Bron, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05661383


Related Trials